Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AIkido Pharma Inc. (AIKI)

3.53   0.11 (3.22%) 12-07 16:00
Open: 3.39 Pre. Close: 3.42
High: 3.57 Low: 3.31
Volume: 89,270 Market Cap: 19(M)

Technical analysis

as of: 2022-12-07 4:20:12 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 5.86     One year: 7.1
Support: Support1: 3.3    Support2: 2.75
Resistance: Resistance1: 5.02    Resistance2: 6.07
Pivot: 3.77
Moving Average: MA(5): 3.47     MA(20): 3.92
MA(100): 5.76     MA(250): 6.54
MACD: MACD(12,26): -0.6     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 10.4     %D(3): 9.3
RSI: RSI(14): 23.4
52-week: High: 11.72  Low: 0.29
Average Vol(K): 3-Month: 77 (K)  10-Days: 33 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AIKI ] has closed above bottom band by 30.8%. Bollinger Bands are 6.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.57 - 3.59 3.59 - 3.61
Low: 3.27 - 3.29 3.29 - 3.31
Close: 3.5 - 3.53 3.53 - 3.56

Company Description

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Headline News

Thu, 01 Dec 2022
Online Platforms Are in the VAT Spotlight in the European Union - Bloomberg Tax

Thu, 24 Nov 2022
aespa, Aiki, and TXT win the Ministry of Culture, Sports, and Tourism Award - allkpop

Thu, 24 Nov 2022
#aespa, #Aiki, and #TXT Win the Ministry of Culture, Sports, and Tourism Award - Latest Tweet by Allkpop - LatestLY

Tue, 22 Nov 2022
2022 MAMA Awards Teases Legendary Stages From KARA, Stray Kids, TXT, And ITZY - soompi

Sun, 18 Sep 2022
Aikido Pharma (AIKI) Stock: Why It Increased 8.29% - Pulse 2.0

Fri, 09 Sep 2022
Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer - PR Newswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 5 (M)
Shares Float 4 (M)
% Held by Insiders 12.2 (%)
% Held by Institutions 10.8 (%)
Shares Short 75 (K)
Shares Short P.Month 58 (K)

Stock Financials

EPS -1.85
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.92
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -9.2
Return on Equity (ttm) -18.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -11 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -1.91
PEG Ratio 0
Price to Book value 0.22
Price to Sales 0
Price to Cash Flow -1.8

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-05-09
Ex-Dividend Date 1980-05-11
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.